ClinicalTrials.gg
RecruitingNCT05890664COLECTRO-AFUpdated May 28, 2025

Colchicine After Electrocardioversion for Atrial Fibrillation

A Phase 3 interventional study of Colchicine and Placebo in Atrial Fibrillation and Cardiac Arrhythmia, sponsored by University Hospital, Basel, Switzerland. Recruiting at 8 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by University Hospital, Basel, Switzerland · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.

Planned enrollment
3rd of 22
416 · median 236
Started
2024
the only one that year
Phase 3
13 of 22
3 open now
Registered
16th of 22
by date

Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 13 in phase 3, and was the 16th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing colchicine in Atrial Fibrillation, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.

Read the detailed description

Atrial fibrillation is the most common cardiac arrhythmia worldwide and is associated with an increased risk of heart failure, stroke and death. Over the next 40 years the investigators expect another increase in the prevalence of atrial fibrillation with a risk of 1:3 in people over 65 years to develop atrial fibrillation. Electroconversion can occur in patients with atrial fibrillation reestablish sinus rhythm acutely with a controlled electrical shock. Unfortunately it is known however, that there is a short-term recurrence of atrial fibrillation in about 60%. This underlines that our current treatment options are inadequate. There is increasing evidence that inflammation is integral to initiation and maintenance of atrial fibrillation. Therefore, the researchers see inflammation as a possible therapeutic target to reduce the recurrence rate of atrial fibrillation after electroconversion. To test this hypothesis and to help patients, the investigators want to conduct the COLECTRO-AF study.

03

Conditions studied

  • Atrial Fibrillation
  • Cardiac Arrhythmia

Keywords

  • Electrocardioversion
  • Colchicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • -documented AF prior to ECV
  • Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV
  • Ability to give written

Exclusion criteria

Exclusion Criteria:

  • AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV
  • Any other rhythm than AF before cardioversion
  • Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV
  • Known intolerance or to Colchicine
  • Any other absolute indication for Colchicine intake
  • Intake of a strong inhibitor of or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole)
  • Serious gastrointestinal disease (severe gastritis or diarrhea)
  • Clinically overt hepatic disease
  • Severe renal disease (\< 30ml/min/1.73m2)
  • blood dyscrasia (e.g., myelodysplasia)
  • Significant (e.g. due to transplantation or rheumatic disease)
  • Pregnant or breastfeeding women, or women of who do not use a highly effective form of
  • \<1 year
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
416 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Study participants in the active study arm will receive a daily oral dose of 0.5 mg Colchicine for 3 months without a loading dose. The dose is recommended to be taken in the morning. There is no deviation from the usual treatment intake.

    Drug: Colchicine

  • Placebo comparator
    Control Group

    Study participants in the placebo group will receive a matched placebo.

    Drug: Placebo

Interventions

  • Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide. Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.

  • DrugPlacebo

    Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.

06

What researchers measure

Primary outcomes

  1. Number of atrial fibrillation (AF) recurrence

    The primary outcome of AF recurrence within 6 months will be assessed based on the ECG (electrocardiogram) documentation of any AF. If a patient reports symptoms of AF recurrence in between the study visits, the research staff will obtain an ECG documentation. The outcome will only be valid if AF recurrence is documented by an ECG.

    Time frame: within 6 month after electrocardioversion

Secondary outcomes

  1. Number of atrial fibrillation (AF) recurrence

    The secondary outcome of AF recurrence within 1 months will be assessed based on the ECG (electrocardiogram) documentation of any AF. If a patient reports symptoms of AF recurrence in between the study visits, the research staff will obtain an ECG documentation. The outcome will only be valid if AF recurrence is documented by an ECG.

    Time frame: within 1 month after electrocardioversion

  2. Number of atrial fibrillation (AF) recurrence

    The secondary outcome of AF recurrence within 3 months will be assessed based on the ECG (electrocardiogram) documentation of any AF. If a patient reports symptoms of AF recurrence in between the study visits, the research staff will obtain an ECG documentation. The outcome will only be valid if AF recurrence is documented by an ECG.

    Time frame: within 3 month after electrocardioversion

  3. Time to first redo electrocardioversion

    Time to first redo electrocardioversion

    Time frame: up to 6 month

  4. Use of antiarrhythmic drugs

    Assessment of medication intake by study staff Vaughan-Williams classification class 1 and 3 of antiarrhythmic drugs will be documented (1 = sodium channel blockade, 3 = potassium channel blockade)

    Time frame: within 6 month after electrocardioversion

  5. Number of survived participants without an unplanned hospital stay

    Number of survived participants without an unplanned hospital stay

    Time frame: up to 6 month

07

Study locations

8 of 8 sites recruiting
  • Cantonal Hospital Baselland (KSBL)
    Bruderholz, Baselland 4101, Switzerland
    Recruiting
    • Christian Maurer, Dr. med. · Contactchristian.maurer@ksbl.ch, · +41 61 436 21 90
    • Christian Maurer, Dr. med. · Principal investigator
  • University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
    • Christian Sticherling, Prof. · Contactchristian.sticherling@usb.ch · +41 61 265 55 26
    • Philipp Krisai, PD Dr. med. · ContactPhilipp.krisai@usb.ch · +41 61 265 25 25
    • Christian Sticherling, Prof. · Principal investigator
    • Philipp Krisai, PD Dr. med. · Sub investigator
  • University Hospital Bern
    Bern, 3010, Switzerland
    Recruiting
  • Lausanne University Hospital
    Lausanne, 1011, Switzerland
    Recruiting
    • Etienne Pruvot, Prof. Dr. · Contactetienne.pruvot@chuv.ch · +41 21 314 11 11
    • Etienne Pruvot, Prof. Dr. · Principal investigator
  • Lucerne Cantonal Hospital
    Luzern, 6000, Switzerland
    Recruiting
    • Ann-Kathrin Gamer, MD · Contactannkathrin.gamer@luks.ch · +41 41 205 18 77
    • Ann-Kathrin Gamer, MD · Principal investigator
  • Cantonal Hospital Olten
    Olten, 4600, Switzerland
    Recruiting
  • Herzpraxis am Rhein
    Rheinfelden, 4310, Switzerland
    Recruiting
    • Flavio Scarcia, MD · Contactherzpraxisamrhein@hin.ch · +41 61 836 99 88
    • Flavio Scarcia, MD · Principal investigator
  • Solothurner Spitäler AG
    Solothurn, 4500, Switzerland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 35 months is below that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2023
First posted
Jun 6, 2023
StartActual
Apr 14, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05890664
Collaborators
Swiss Heart Foundation, Fondation Machaon, Switzerland, Genf, Foundation for Cardiovascular Research Basel
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Apr 14, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 28, 2025

Study contacts

Philipp Krisai, PD Dr. med.
Contact
Philipp.krisai@usb.ch
+41 61 265 25 25
Philipp Krisai, PD Dr. med.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion